BPMC News and Press, Blueprint Medicines Corporation From 10/26/23

2023-10-26 14:11:01 ET Blueprint Medicines Corporation (BPMC) Q3 2023 Earnings Conference Call October 26, 2023 08:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercia...

2023-10-26 12:53:31 ET Gainers: MSP Recovery ( LIFW ) +31% . Blueprint Medicines Corp ( BPMC ) +27% . Global Mofy Metaverse Ltd ( GMM ) +23% . Endeavor Group Holdings ( EDR ) +23% . Impinj ( PI ) +22% . Bel Fuse ( BELFB )...

2023-10-26 11:23:02 ET Blueprint Medicines ( NASDAQ: BPMC ) shares jumped 23% on Thursday after a better-than-expected Q3 report . The Massachusetts-based precision therapy company generated revenue of $56.6M, which fell 14.2% Y/Y but met Wall Street estimates. Sales of ...

2023-10-26 07:11:04 ET More on Blueprint Medicines Blueprint Medicines: Rating Downgrade Amid Growth Concerns Blueprint Medicines: At The Forefront Of Groundbreaking Cancer Treatments Blueprint Medicines Corporation 2023 Q2 - Results - Earnings Call Presentation ...

CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...

Blueprint Medicines Reports Third Quarter 2023 Results PR Newswire -- Achieved $54.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues, representing 90% growth year-over-year, and $56.6 million in total revenues in the third quarter of 2023 ...

Blueprint Medicines Corporation (BPMC) is expected to report $-2.39 for Q3 2023

2023-10-25 14:16:50 ET More on Blueprint Medicines Blueprint Medicines: Rating Downgrade Amid Growth Concerns Blueprint Medicines: At The Forefront Of Groundbreaking Cancer Treatments Blueprint Medicines Corporation 2023 Q2 - Results - Earnings Call Presentation ...

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board PR Newswire SAN JOSE, Calif. , Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA...

Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 PR Newswire CAMBRIDGE, Mass. , Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call a...